Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $7.3 million.

  • Ocular Therapeutix's Interest & Investment Income rose 5720.4% to $7.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.4 million, marking a year-over-year decrease of 951.09%. This contributed to the annual value of $18.4 million for FY2025, which is 950.1% down from last year.
  • As of Q4 2025, Ocular Therapeutix's Interest & Investment Income stood at $7.3 million, which was up 5720.4% from $3.7 million recorded in Q3 2025.
  • Ocular Therapeutix's Interest & Investment Income's 5-year high stood at $7.3 million during Q4 2025, with a 5-year trough of $6000.0 in Q4 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $980000.0 (2023), whereas its average is $2.2 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first plummeted by 9136.69% in 2021, then surged by 695000.0% in 2022.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Interest & Investment Income stood at $6000.0 in 2021, then skyrocketed by 6950.0% to $423000.0 in 2022, then soared by 244.92% to $1.5 million in 2023, then skyrocketed by 220.15% to $4.7 million in 2024, then soared by 57.2% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q4 2025, $3.7 million for Q3 2025, and $3.5 million during Q2 2025.